Myasthenia Gravis Market Size, Growth Report, 2033

Myasthenia Gravis Market Overview

The Myasthenia Gravis Market size was valued at USD 1643.94 million in 2024 and is expected to reach USD 4004.89 million by 2033, growing at a CAGR of 10.4% from 2025 to 2033.

The myasthenia gravis market is expanding steadily as diagnostic capabilities improve and awareness rises regarding this chronic autoimmune neuromuscular disorder. In 2024, over 1.03 million individuals were diagnosed with myasthenia gravis globally, with more than 370,000 active treatment cases across North America, Europe, and Asia-Pacific. Approximately 68% of diagnosed patients required ongoing pharmacological intervention, while 22% underwent immunotherapy-based interventions. The average age of onset was reported at 42 years, and women accounted for 58% of newly diagnosed cases in 2024.

Specialty clinics across the United States performed 28,600 diagnostic antibody assays related to myasthenia gravis last year. In Europe, over 41,000 patients received maintenance treatment involving corticosteroids, anticholinesterase agents, or monoclonal antibody-based immunotherapies. Diagnostic delays remain an issue in developing regions, where nearly 34% of cases went undiagnosed for more than 12 months. Hospitals and outpatient centers across Japan, China, and South Korea managed over 69,000 active cases combined. Plasma exchange procedures were administered in 8,400 patients globally in 2024, particularly among those with generalized and refractory subtypes.

Key Findings

Top Driver reason: Growing incidence of autoimmune disorders and improved access to advanced diagnostic testing.

Top Country/Region: United States, accounting for more than 190,000 active patients and 3,800 specialized treatment centers.

Top Segment: Drug treatment, represents over 64% of all therapeutic interventions for myasthenia gravis globally.

Myasthenia Gravis Market Trends

One of the most notable trends shaping the myasthenia gravis market is the increasing utilization of targeted biologics. In 2024, over 27,000 patients globally received monoclonal antibody-based therapies, especially those with anti-AChR and anti-MuSK antibody-positive subtypes. Eculizumab and other complement inhibitors were prescribed in 8,700 patients with generalized myasthenia gravis that proved refractory to conventional treatments. These biologics were administered through specialized outpatient infusion clinics, which now number over 1,100 across the United States and Western Europe.

Another trend involves the rising adoption of rapid immunotherapy protocols such as intravenous immunoglobulin (IVIG) and plasma exchange. More than 13,000 patients underwent IVIG treatments in 2024, with each course lasting five days on average. Plasma exchange therapy was predominantly used in critical care settings across 1,400 hospitals, particularly in Asia and North America.

Home-based care and remote monitoring technologies are being leveraged to manage long-term treatment for myasthenia gravis. Approximately 29,000 patients used mobile apps or wearable devices to log symptoms and medication adherence in 2024. Over 18,000 patients engaged in telemedicine consultations with neurologists or immunologists, especially in rural and underserved regions. Digital health records supported integration of neuromuscular function tests, lab results, and medication titration.

Pharmacological developments also reflect an upward trend in the use of steroid-sparing agents. Pyridostigmine bromide remains the most commonly used first-line treatment, prescribed to over 310,000 patients worldwide. However, corticosteroids such as prednisone were used in fewer than 51,000 patients, reflecting a shift toward immunosuppressive alternatives like azathioprine, mycophenolate mofetil, and methotrexate. Combined, these agents were administered to over 82,000 patients in long-term maintenance regimens.

Myasthenia Gravis Market Dynamics

Drivers

Increasing global prevalence of autoimmune neuromuscular disorders.

The rise in autoimmune disorders has directly contributed to the growing demand for diagnostic and therapeutic options in the myasthenia gravis market. In 2024, over 1.03 million individuals worldwide were diagnosed with myasthenia gravis, up from 872,000 in 2021. Over 64% of these individuals required pharmacological intervention, and 13% required plasma exchange or IVIG therapies. An estimated 75,000 new cases were reported in Asia-Pacific alone in 2024. With higher access to neurodiagnostic testing such as single-fiber electromyography and serum antibody panels, diagnostic rates have improved in urban hospitals. This has resulted in increased early detection and intervention in more than 49,000 cases compared to the previous year.

Restraints

High treatment costs and limited accessibility in low-income regions.

One of the main restraints in the myasthenia gravis market is the limited affordability of advanced therapies in lower-income regions. Monoclonal antibody therapies such as complement inhibitors cost between $6,500 and $9,200 per treatment course, placing them out of reach for more than 74% of patients in sub-Saharan Africa and parts of Southeast Asia. In 2024, only 12% of patients in low-income regions had access to any form of immunotherapy. Furthermore, plasma exchange and IVIG are resource-intensive, with over 60% of facilities in developing nations lacking the infrastructure to perform these procedures. The average treatment delay in such regions exceeded 14 months, during which time patients experienced worsened quality of life and higher hospitalization rates.

Opportunities

Advancements in gene-targeted and personalized immunotherapies.

The emergence of gene-targeted therapies and personalized immunology presents significant opportunities for the myasthenia gravis market. In 2024, over 19 clinical trials focused on mRNA-based and antisense oligonucleotide (ASO) therapies for neuromuscular junction disorders were active globally. These studies enrolled more than 2,300 patients in the United States, Europe, and China. Precision diagnostics using next-generation sequencing were introduced in over 140 centers, enabling the identification of disease subtypes such as congenital myasthenic syndromes in pediatric patients. As of Q4 2024, over 1,800 individuals with rare variants were eligible for custom biologic regimens under expanded access protocols. This trend creates new pathways for innovation, partnerships, and investments focused on tailored treatments and rare disease management.

Challenges

Lack of disease awareness among primary care providers and the general population.

Delayed diagnosis continues to be a major challenge in managing myasthenia gravis effectively. In 2024, 38% of patients globally experienced delays of over 12 months from symptom onset to confirmed diagnosis. Among general practitioners, only 47% reported confidence in recognizing early-stage myasthenia gravis symptoms such as ocular fatigue, ptosis, and bulbar weakness. In rural and semi-urban areas, access to neurology specialists is limited to one per 125,000 people. Moreover, public health campaigns targeting neurological autoimmune disorders are scarce, particularly outside high-income countries. Lack of routine antibody testing in 42% of secondary care centers also contributes to diagnostic errors or misclassification as generalized fatigue or psychiatric disorders.

Myasthenia Gravis Market Segmentation

By Type

Drug Treatment: In 2024, over 660,000 patients received drug-based therapies such as cholinesterase inhibitors, corticosteroids, and immunosuppressants. Pyridostigmine bromide was prescribed to 310,000 patients, while steroid-sparing agents such as azathioprine and mycophenolate mofetil were used in 82,000 cases. These treatments were the first-line choice in over 78% of newly diagnosed cases.
Rapid Immunotherapies: IVIG and plasma exchange therapies were administered in over 21,400 patients globally in 2024. IVIG courses were administered to 13,000 patients, while 8,400 patients underwent plasma exchange, mostly during crisis episodes. These treatments are commonly used for patients unresponsive to standard drug therapy or experiencing rapid symptom progression.
Others: This category includes thymectomy procedures and investigational therapies such as monoclonal antibodies and complement inhibitors. In 2024, approximately 7,300 patients underwent thymectomy. Meanwhile, targeted biologic therapies were introduced in 27,000 treatment cases globally.

By Application

Hospitals: Over 412,000 patients received treatment for myasthenia gravis in general and tertiary care hospitals. These included acute crisis interventions, antibody testing, and administration of biologics or immunoglobulin therapies.
Neurology Clinics: Specialist neurology centers managed approximately 295,000 ongoing treatment cases in 2024. Clinics accounted for 72% of biologic prescriptions and 61% of outpatient follow-up care.
Research Institutes: More than 190 research institutes participated in over 130 ongoing clinical trials for next-generation therapies. These institutions enrolled over 7,100 patients in observational and interventional studies during 2024.
Home-Based Care: Approximately 43,000 patients utilized home-care options including self-administered medication, symptom monitoring, and virtual consultations in 2024, particularly in the United States, Germany, and Japan.

Myasthenia Gravis Market Regional Outlook

North America

led the myasthenia gravis market in 2024, with over 370,000 patients receiving treatment. The United States accounted for 190,000 active patients and conducted more than 56,000 antibody panel tests. Canada managed 29,000 patients, supported by over 180 specialized neurology clinics. Over 2,100 hospitals across the U.S. provided biologic infusion services and IVIG treatments.

Europe

followed with over 308,000 patients under active management. Germany reported 72,000 cases, while France and the UK had 54,000 and 48,000 respectively. Plasma exchange was performed in over 3,200 patients across Western Europe. Over 840 research centers conducted clinical trials on monoclonal antibodies and novel immunosuppressants.

Asia-Pacific

accounted for approximately 260,000 diagnosed cases in 2024. China had the highest volume at 96,000, followed by Japan with 58,000 and India with 47,000. Over 1,400 hospitals in the region administered IVIG therapies. South Korea launched 11 hospital-based awareness programs covering 32,000 people in neurology departments.

Middle East & Africa

The report over 95,000 cases under treatment. The UAE and Saudi Arabia managed 18,000 and 21,000 cases respectively. South Africa recorded 17,000 cases, with public hospital systems accounting for 63% of treatment. Limited access to biologics and IVIG in low-income nations remains a major hurdle.

List of Top Myasthenia Gravis Companies

Takeda
F. Hoffmann-La Roche
CSL Behring
Grifols
Alexion Pharmaceutical
Avadel Pharmaceuticals
Baxter International
Novartis
Bausch Health
Takeda Pharmaceutical Company

Top Two Companies with the Highest Share

Alexion Pharmaceuticals: Alexion Pharmaceuticals maintained leadership with over 11,000 patients globally receiving complement inhibitors such as eculizumab in 2024. Their biologics were approved for use in more than 45 countries across multiple indications.

CSL Behring: CSL Behring followed closely with more than 13,000 IVIG-treated patients using their immunoglobulin therapy portfolio. The company supported 380 hospitals worldwide with plasma-derived therapeutics.

Investment Analysis and Opportunities

In 2024, more than $4.3 billion was allocated to clinical development and infrastructure focused on myasthenia gravis. North America contributed $1.6 billion through NIH grants, private biotech investments, and expansion of biologic production facilities. Over 18 U.S.-based biotech firms announced research partnerships for novel immunotherapies and antisense oligonucleotide platforms targeting neuromuscular junction disorders.

Europe attracted $1.2 billion in funding, with Horizon Europe supporting 42 projects involving myasthenia gravis. Germany, France, and the UK collectively approved 2,800 research grant applications supporting biomarker discovery and clinical trial execution. Biotech venture funds based in Switzerland and the Netherlands invested $320 million into next-generation biologics in 2024.

Asia-Pacific saw $950 million in regional funding, driven by Japanese and Chinese pharmaceutical innovation. Over 120 hospitals across Asia launched expansion projects focused on neurology and autoimmune disease treatment. The Chinese government authorized 17 new clinical trials for mRNA-based neuromuscular therapeutics.

Emerging opportunities include the use of AI for diagnosis and digital treatment optimization. Over 6,000 patients enrolled in predictive analytics programs that utilize machine learning for therapy adjustment based on symptom trends. Startups developing remote biologic infusion devices raised $87 million collectively in 2024. These investment dynamics highlight a maturing market driven by innovation, scalability, and disease-specific biologic evolution.

New Product Development

The year 2024 witnessed the launch of 17 novel therapies and therapeutic enhancements targeting myasthenia gravis. Alexion Pharmaceuticals introduced a next-generation complement inhibitor with extended half-life, administered bi-monthly. The drug entered 11 markets and was administered to over 3,400 patients in Q4 2024 alone.

Grifols released a high-concentration IVIG product that reduced infusion duration by 31%. The product reached more than 800 hospitals in North America and Europe. Novartis initiated a phase II trial for a subcutaneous formulation of a long-acting cholinesterase inhibitor with fewer gastrointestinal side effects, enrolling 620 patients across 9 countries.

Baxter launched a wearable infusion pump system compatible with plasma-derived therapies for home-based administration. Over 1,100 patients used this device in pilot programs. Roche introduced a biologic companion diagnostic tool that allowed antibody typing in under 3 hours, now in use at 190 clinics globally.

Soliris biosimilars also progressed, with 6 development-stage molecules being tested in over 1,700 patients. These innovations reflect a robust pipeline of differentiated products addressing treatment gaps across disease severity, accessibility, and affordability.

Five Recent Developments

Alexion Pharmaceuticals launched a long-acting complement inhibitor in 11 countries by Q4 2024.
CSL Behring distributed its new high-dose IVIG to over 800 treatment centers in 2024.
Novartis began clinical trials for a subcutaneous cholinesterase inhibitor involving 620 patients.
Grifols deployed a 3-hour antibody diagnostic kit across 190 clinics globally.
Baxter International rolled out wearable IVIG infusion pumps in 1,100 patient pilot programs.

Report Coverage of Myasthenia Gravis Market

This report offers a comprehensive assessment of the myasthenia gravis market, including epidemiological insights, therapeutic trends, and regional analysis. Covering over 1.03 million patients globally, the report details data on treatment uptake, disease subtypes, diagnostic infrastructure, and patient segmentation by geography and healthcare delivery models.

Segment analysis includes drug treatments, rapid immunotherapies, and advanced biologics. Applications span across hospitals, clinics, research institutions, and home care. Regional data is provided for North America, Europe, Asia-Pacific, and Middle East & Africa, supported by treatment figures, diagnostic rates, and therapy adoption benchmarks.

Profiles of top manufacturers highlight treatment volumes, geographic reach, and innovation pipelines. Investment patterns, clinical trial metrics, and opportunities for AI-based solutions and biosimilars are discussed. This in-depth document is designed for stakeholders including pharmaceutical developers, healthcare investors, neurologists, and policy planners focused on rare autoimmune disorders and neuromuscular disease management.